Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III neoadjuvant osimertinib with or without chemotherapy versus chemotherapy alone in resectable EGFR-mutated non-small cell lung cancer
jRCT2080225229Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2020
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of osimertinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by AstraZeneca. Started Jun 2020; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080225229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225229.